Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00308074 · ClinicalTrials.gov registry record · Phase 2
An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders
A Phase 2 study of Autism and Pervasive Developmental Disorder, sponsored by Cambridge Health Alliance.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT00308074 is a Phase 2 study of Autism and Pervasive Developmental Disorder that has completed, run by Cambridge Health Alliance. The registered enrollment target is 14 participants, below the 183-participant average among 104 other Autism trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00308074, a Phase 2 study of Autism and Pervasive Developmental Disorder, has completed, sponsored by Cambridge Health Alliance.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to evaluate the efficacy, safety and tolerability of aripiprazole monotherapy in the treatment of children and adolescents suffering from Autism Spectrum Disorder (ASD) over a 12-week period. We hypothesize that aripiprazole may be helpful in reducing ASD-associated symptoms of anxiety and aggression, resulting in significant improvements in global outcome.
Conditions Studied
Interventions
- DRUG Aripiprazole
Study Locations (1)
Massachusetts
- Cambridge Health Alliance - Medford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2006-02 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00308074
The ClinicalTrials.gov registry entry for NCT00308074 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 183-participant average among 104 other Autism trials with a reported enrollment target (92% lower). The listed sponsor is Cambridge Health Alliance, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Autism appearing as the primary indexed condition, and to 1 intervention - of which Aripiprazole is the first listed.
NCT00308074 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00308074 about?
NCT00308074 is a clinical study titled "An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders". The aim of this study is to evaluate the efficacy, safety and tolerability of aripiprazole monotherapy in the treatment of children and adolescents suffering from Autism Spectrum Disorder (ASD) over a 12-week period. We hypothesize that aripiprazole may be helpful in reducing ASD-associated symptoms...
What is the current status of trial NCT00308074?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2006-02. Estimated completion is 2009-02.
What conditions does trial NCT00308074 study?
This clinical trial studies the following conditions: Autism, Pervasive Developmental Disorder, Asperger's Disorder.
What interventions are being tested in trial NCT00308074?
The interventions under investigation include: Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00308074?
This trial is sponsored by Cambridge Health Alliance, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00308074 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Optimizing Outcomes for Young Autistic Children
RECRUITING · Phase 2
-
The Impact of a Virtual Magic Trick Training Program
RECRUITING · Phase 2
-
Trial of Zolpidem for Sleep in Children With Autism
RECRUITING · Phase 2
-
A Study of Esomeprazole in Children With Autism
RECRUITING · Phase 2
-
Trial of Diphenhydramine for Sleep in Children With Autism
RECRUITING · Phase 2
-
Trial of Suvorexant for Sleep in Children With Autism
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.